CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Fludarabine +2 moredrug
Likely dose
Fludarabine 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00429572
NCT00429572Phase 2Completed
CompareCT.gov

Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer

M.D. Anderson Cancer Center·interventional·Posted Jan 31, 2007·Updated Aug 7, 2012

In Brief

A Phase 2 clinical trial evaluating Fludarabine, Melphalan, and 1 other intervention for Breast Cancer. Completed, enrolled 19 participants across 1 site.

Detailed Summary

Primary Objectives: 1. To assess the feasibility of mini-allogeneic Peripheral Blood Progenitor Cell (PBPC) transplantation in patients with recurrent or metastatic breast cancer. 2. To determine the success rate (complete remission without severe toxicity or death) at 100 days after the transplant and long-term progression free survival (PFS) rate. 3. To examine the graft vs. breast cancer effect of allogeneic PBPC transplantation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 31, 2007
Enrollment StartJan 1, 1998
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10.3 yearsPosted 19.4 years ago

Interventions

Fludarabinedrug

30 mg/m\^2 intravenously Daily for 5 Days

Melphalandrug

70 mg/m\^2 intravenously Daily for 2 Days

Stem Cell Infusionprocedure

Stem Cell Infusion on Day 0.